Brought to you by 
Rubius closes Series C round of more than $100mm
Mar 2018
Executive Summary
Rubius Therapeutics Inc. (cell therapies) raised $101.2mm in an oversubscribed Series C financing. According to the Form D, 27 investors participated. The company is developing Red-Cell Therapeutics (RCT) allogeneic products with extended stability and storage. Rubius will use the funds to move RTC therapies into the clinic and enhance its manufacturing capabilities.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rubius closes Series C round of more than $100mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice